A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
NCT01629615
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
BKM120
Sponsor
SOLTI Breast Cancer Research Group
Collaborators
[object Object]
[object Object]
[object Object]